# Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma

> **NCT05488366** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, Irvine** · enrollment: 9 (actual)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT05488366
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-03
- **Primary completion:** 2025-06-27
- **Final completion:** 2026-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05488366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05488366, "Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05488366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*